ResearcherMeiji Pharmaceutical UniversityNo recent work listed
Ai Irisawa
Matched on OpenAlex author ID A5050074861. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper
Papers 3
- Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1038/s41598-022-18669-9↗
- The "histological replacement growth pattern" represents aggressive invasive behavior in liver metastasis from pancreatic cancer. Co-author DOI 10.1002/cam4.2954↗
- Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00520-018-4248-4↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Shuichi Mitsunaga · 3 shared papers, 2018–2022 · strength 0.37
- Paper Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients … DOI 10.1038/s41598-022-18669-9↗
- Paper The "histological replacement growth pattern" represents aggressive invasive behavior in liver metastasis from pancreat… DOI 10.1002/cam4.2954↗
- Paper Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer. DOI 10.1007/s00520-018-4248-4↗
- Masafumi Ikeda · 3 shared papers, 2018–2022 · strength 0.37
- Paper Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients … DOI 10.1038/s41598-022-18669-9↗
- Paper The "histological replacement growth pattern" represents aggressive invasive behavior in liver metastasis from pancreat… DOI 10.1002/cam4.2954↗
- Paper Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer. DOI 10.1007/s00520-018-4248-4↗
- Hidetaka Suzuki · 2 shared papers, 2018–2020 · strength 0.18
- Atsushi Ochiai · 2 shared papers, 2018–2020 · strength 0.18
- Kazuo Watanabe · 1 shared paper, 2020 · strength 0.10
- Mitsuhito Sasaki · 1 shared paper, 2020 · strength 0.10
- Motohiro Kojima · 1 shared paper, 2020 · strength 0.10
- Hiroshi Imaoka · 1 shared paper, 2020 · strength 0.10
- Tetsuo Akimoto · 1 shared paper, 2020 · strength 0.10
- Tomofumi Miura · 1 shared paper, 2018 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.